The company remains entirely pre-revenue, with quarterly R&D expenses climbing to $14.6 million in 2025Q4, contributing to a widened net loss of $25.3 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 84.21M | 40M | 31.67M | 12.82M | 9.8M | 5.74M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 38.83M | 10.06M | 6.82M | 3.95M | 2.38M | 2.06M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 45.38M | 29.94M | 24.84M | 8.87M | 7.42M | 3.69M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -84.21M | -40M | -31.67M | -12.82M | -9.8M | -5.74M |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | -110.54% | -26.3% | -147% | -30.87% | -70.59% | - |
| EBITDA | -83.74M | -39.55M | -31.27M | -12.62M | -9.77M | -5.73M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | -111.76% | -26.47% | -147.71% | -29.24% | -70.57% | - |
| D&A (Non-Cash Add-back) | 464K | 449K | 399K | 198K | 30K | 17K |
| EBIT | -77.61M | -36.12M | -31.6M | -12.63M | -9.67M | -5.74M |
| Net Interest Income | 0 | 3.72M | 49K | 7K | 5K | -9K |
| Interest Income | 0 | 3.74M | 74K | 23K | 5K | 12K |
| Interest Expense | 0 | 20K | 25K | 16K | 0 | 21K |
| Other Income/Expense | 6.6M | 3.86M | 45K | 173K | 131K | -9K |
| Pretax Income | -77.61M | -36.14M | -31.62M | -12.65M | -9.67M | -5.75M |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 6K | 9K | 0 | 0 | 1K |
| Effective Tax Rate % | 0% | -0.02% | -0.03% | 0% | 0% | -0.02% |
| Net Income | -77.61M | -36.14M | -31.63M | -12.65M | -9.67M | -5.75M |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | -114.73% | -14.26% | -150.09% | -30.85% | -68.02% | - |
| Net Income (Continuing) | -77.61M | -36.14M | -31.63M | -12.65M | -9.67M | -5.75M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.31 | -1.18 | -1.19 | -0.63 | -0.40 | -0.62 |
| EPS Growth % | -95.76% | 0.84% | -88.89% | -57.5% | 35.48% | - |
| EPS (Basic) | -2.31 | -1.18 | -1.19 | -0.63 | -0.40 | -0.62 |
| Diluted Shares Outstanding | 33.54M | 30.54M | 26.59M | 19.98M | 24.1M | 9.21M |
| Basic Shares Outstanding | 33.54M | 30.54M | 26.59M | 19.98M | 24.1M | 9.21M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Binary clinical trial outcomes
As reported in recent financial statements, Belite Bio's quarterly research and development expenses have climbed to $14.6 million by 2025Q4, reflecting the intensified operational demands of concurrent Phase 3 clinical programs that continue to drive the company's significant cash burn without any offsetting commercial revenue streams.
The steady rise in R&D spending suggests a scaling of clinical trial activities, likely tied to patient enrollment and site management for the DRAGON and PHOENIX programs. Investors should monitor whether these costs stabilize as trials reach maturity or if further inflationary pressures in clinical labor markets necessitate additional capital.
Based on the company's reported figures, operating losses have widened to $28.1 million in 2025Q4, demonstrating that the firm's current cost structure is entirely decoupled from revenue generation as it prioritizes long-term asset development over near-term operational efficiency or the achievement of positive operating leverage.
The expansion of SG&A expenses alongside R&D indicates a growing administrative footprint, which may be necessary for global regulatory readiness but adds to the overall burn rate. This trajectory implies that the company remains in a high-risk phase where operational scale is currently a liability rather than a source of efficiency.
According to recent SEC filings, the emergence of stock-based compensation, reaching $11.7K in 2025Q4, warrants close scrutiny as it introduces a non-cash expense that, while currently modest, may signal a shift toward equity-based incentives that could dilute shareholder value as the company advances its clinical pipeline.
While the current impact on net income is minimal, the introduction of SBC suggests management is aligning compensation with long-term milestones. Analysts should evaluate whether this trend accelerates, as it could complicate future earnings-per-share projections once the company eventually transitions to a commercial stage.
While the company maintains a $352.9 million cash position, the rapid acceleration of quarterly net losses to $25.3 million in 2025Q4 suggests that the current runway may be shorter than anticipated if clinical trial timelines extend or if regulatory requirements for data collection become more stringent.
Short-term observers might focus on the lack of revenue as a primary risk, but the more critical concern is the potential for 'lumpy' cash outflows related to CRO milestones. The absence of debt is a positive, yet it leaves the company entirely reliant on equity markets should the current cash reserves prove insufficient to reach a commercial inflection point.
Quick answers to the most common questions about buying BLTE stock.
For fiscal year 2025, Belite Bio, Inc (BLTE) reported total revenue of $0.0M.
Belite Bio, Inc (BLTE) reported a net loss of $77.6M for the fiscal year ending 2025.